Apyx Medical (APYX) Q1 2026 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Fri, May 8, 2026 astatine 10:16 AM CDT 19 min read

Image source: The Motley Fool.

DATE

Thursday, May 7, 2026 astatine 8 a.m. ET

CALL PARTICIPANTS

• President and Chief Executive Officer — Charles D. Goodwin

• Chief Financial Officer — Matthew Hill

Full Conference Call Transcript

Charles Goodwin: Thank you, Jeremy, and convey you each for joining america today. For our accustomed format connected these quarterly calls, I volition statesman with a reappraisal of our show implicit the past respective months and past crook the telephone implicit to Matt for a reappraisal of our archetypal 4th 2026 fiscal results, on with our updated guidance for afloat twelvemonth 2026. We volition past unfastened the telephone for your questions. Let maine statesman with a reappraisal of a fewer cardinal highlights from our archetypal 4th 2026 performance. We reported full quarterly gross of $12.5 cardinal compared to $9.4 cardinal successful the aforesaid play past year.

This maturation was driven by a 36% summation successful income of our Surgical Aesthetics products to $10.7 cardinal for the archetypal quarter, which was chiefly attributable to the continued beardown income ramp of our AYON assemblage contouring strategy successful the U.S., request for single-use handpieces worldwide and summation successful Renuvion generator income internationally. This represents our 2nd afloat 4th of AYON income pursuing its afloat commercialized motorboat successful September 2025. Notably, portion request from our existing generator and Renuvion lawsuit basal continues to beryllium strong, we are besides generating a dependable summation successful engagement from caller accounts, reflecting increasing marketplace consciousness of AYON and expanding assurance successful the breadth of its capabilities.

Importantly, we proceed to judge adoption remains successful the aboriginal stages. Over these past respective months, I person been precise pleased by however the commercialized programme for AYON has rapidly ramped up activity. Our squad has risen to the juncture and executed a disciplined, high-quality motorboat focused connected grooming and workflow integration to execute lawsuit success. We are besides pleased the merchandise of AYON has coincided truthful good with the continued accelerated adoption of GLP-1s. As of aboriginal 2026, astir 1 successful 8 U.S. adults study person taken a GLP-1 according to KFF wellness tracking polls and RAND reports.

While astir 6% of adults are presently utilizing them, projections bespeak that request volition proceed to turn with estimates suggesting astir 30 cardinal Americans could beryllium utilizing GLP-1 treatments by 2030. The accelerated value nonaccomplishment that occurs utilizing these drugs tin pb to important escaped and lax tegument that tin lone beryllium efficaciously managed utilizing a surgical intervention, and we judge Renuvion and AYON are the astir precocious and effectual method for treating escaped and lax tegument done assemblage contouring. In summation to our gross growth, we stay arrogant of the thin operating operation we implemented conscionable implicit a twelvemonth ago, which has materially reduced our operating expenses and currency burn.